Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates. The Company's lead product candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. Unlike current therapies that risk cardiotoxicity and can have their effectiveness limited due to multidrug resistance, Annamycin appears capable of avoiding both of these problems and has already demonstrated the ability to save lives in clinic.
|Employees (est.) (Dec 2018)||9||(+350%)|
|Share Price (Jun 2019)||$1.2|
Net income (FY, 2018)
EBIT (FY, 2018)
Market capitalization (10-Jun-2019)
Closing stock price (10-Jun-2019)
Moleculin Biotech has 593 Twitter Followers. The number of followers has decreased 0.3% month over month and increased 0.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Moleculin Biotech founded?
Moleculin Biotech was founded in 2006.
Who are Moleculin Biotech key executives?
Moleculin Biotech's key executives are Donald Picker, Robert Shepard and Sandra Silberman.
How many employees does Moleculin Biotech have?
Moleculin Biotech has 9 employees.
Who are Moleculin Biotech competitors?
Competitors of Moleculin Biotech include Vivace Therapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.
Where is Moleculin Biotech headquarters?
Moleculin Biotech headquarters is located at 2575 W Bellfort Ave #333, Houston.
Where are Moleculin Biotech offices?
Moleculin Biotech has an office in Houston.
How many offices does Moleculin Biotech have?
Moleculin Biotech has 1 office.
Receive alerts for 300+ data fields across thousands of companies